Work

Small intestinal bacterial overgrowth produces symptoms in irritable bowel syndrome which are improved by rifaximin. A pilot study.

Year: 2013

Type: article

Study design: Clinical Trial

Source: PubMed

Authors: Ioana G Moraru, P Portincasa, A G Moraru, M Diculescu, D L Dumitraşcu

Language: English

Topic: Gastrointestinal motility and disorders

Subfield: Gastroenterology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W962900825

FWCI: 1.026

Cites: 20

Cited by: 16

Related to: 10